Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Down 5.6% in October

Esperion Therapeutics, Inc. (NASDAQ:ESPR) was the recipient of a large drop in short interest in October. As of October 15th, there was short interest totalling 35,390,000 shares, a drop of 5.6% from the September 30th total of 37,470,000 shares. Currently, 18.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 3,640,000 shares, the days-to-cover ratio is currently 9.7 days.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Bellevue Group AG grew its holdings in shares of Esperion Therapeutics by 136.5% during the 1st quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after acquiring an additional 5,739,800 shares during the period. Vanguard Group Inc. grew its stake in Esperion Therapeutics by 71.8% in the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after purchasing an additional 3,688,796 shares during the period. Marshall Wace LLP raised its holdings in Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after purchasing an additional 2,087,635 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Esperion Therapeutics by 3,278.3% during the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after buying an additional 555,382 shares during the period. Finally, XTX Topco Ltd boosted its holdings in shares of Esperion Therapeutics by 751.6% during the 2nd quarter. XTX Topco Ltd now owns 364,681 shares of the biopharmaceutical company’s stock valued at $810,000 after buying an additional 321,859 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Trading Down 0.5 %

ESPR stock opened at $2.03 on Friday. The firm’s 50-day moving average price is $1.87 and its two-hundred day moving average price is $2.12. The stock has a market capitalization of $398.35 million, a price-to-earnings ratio of -2.36 and a beta of 1.00. Esperion Therapeutics has a 12-month low of $0.85 and a 12-month high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million. Equities analysts predict that Esperion Therapeutics will post -0.09 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on ESPR shares. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Wednesday, October 2nd. Needham & Company LLC cut their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. Finally, StockNews.com raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, October 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.